Department of Dermatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Rheumatology (Oxford). 2011 Aug;50(8):1366-72. doi: 10.1093/rheumatology/ker116. Epub 2011 Apr 12.
The Th17 lineage, a lineage of effector CD4(+) T cells, is characterized by the production of IL-17. Expansion of Th17 cells has been implicated in a growing list of autoimmune disorders. Our studies, as well as others, have shown that Th17 cells play a key role in the pathogenesis of SLE. Therefore, some investigators advocate that Th17 cells are a promising therapeutic target for SLE. However, neutralization of IL-17 in vivo actually aggravated inflammation by inducing infiltration of other effector cells. Thus, the therapeutic effects of antagonizing Th17 cells for the treatment of SLE in the clinic are worth discussing. Moreover, in patients with SLE, the expansion of effector T cells is always closely related to the depletion and dysfunction of Treg cells. Therefore, we hypothesize that for the treatment of SLE, we should focus on therapeutic agents that can regulate the immune balance between Th17 and Treg cells rather than on those that exclusively regulate Th17 cells.
Th17 细胞是效应性 CD4(+)T 细胞的一个亚群，其特征是能够分泌白细胞介素-17（IL-17）。越来越多的自身免疫性疾病都与 Th17 细胞的扩增有关。我们的研究以及其他研究表明，Th17 细胞在系统性红斑狼疮（SLE）的发病机制中发挥着关键作用。因此，一些研究人员主张将 Th17 细胞作为治疗 SLE 的一个有前途的靶点。然而，体内中和 IL-17 实际上通过诱导其他效应细胞的浸润而加重了炎症。因此，临床上拮抗 Th17 细胞治疗 SLE 的疗效值得探讨。此外，在 SLE 患者中，效应性 T 细胞的扩增总是与 Treg 细胞的耗竭和功能障碍密切相关。因此，我们假设，对于 SLE 的治疗，我们应该关注能够调节 Th17 和 Treg 细胞之间免疫平衡的治疗药物，而不是专门调节 Th17 细胞的药物。
